Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Statin

Therapeutic area intelligence for Statin with 9 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
9
Catalysts
0
Companies
8

Companies

Alkem Labs →
AstraZeneca →
Aurobindo Pharma →
Macleods Pharmaceuticals →
Mankind Pharma →
Sciegen Pharmaceuticals →
Sun Pharma →
Torrent Pharmaceuticals →

Assets

Aurobindo →
CRESTOR →
FDA →
Rosuvastatin →
Torrent →

Recent signals

(9)
StrategyAugust 5, 2026

Mankind Pharma's Rosuvastatin Calcium ANDA206603 Receives AP Status

Mankind Pharma's ANDA for Rosuvastatin Calcium has been granted Abbreviated Approval (AP) status by the FDA.

StrategyAugust 5, 2026

Aurobindo Pharma's Rosuvastatin Calcium Supplement Application Approved by FDA

The FDA has approved Aurobindo Pharma's supplemental application for Rosuvastatin Calcium.

StrategyAugust 5, 2026

Torrent's Rosuvastatin Calcium ANDA Receives Approval Status

Torrent's ANDA201619 for Rosuvastatin Calcium has received an approval status (AP) from the FDA.

RegulatoryAugust 5, 2026

FDA Accepts Supplement for Rosuvastatin Calcium by Alkem Labs

The FDA has accepted a supplemental application for Rosuvastatin Calcium from Alkem Labs.

RegulatoryJuly 31, 2026

FDA Acceptance of Supplemental NDA for CRESTOR by AstraZeneca

The FDA has accepted a supplemental NDA for CRESTOR (rosuvastatin calcium) submitted by AstraZeneca.

RegulatoryJuly 24, 2026

FDA Accepts Supplement for Rosuvastatin Calcium by Macleods

The FDA has accepted a supplemental application for Rosuvastatin Calcium from Macleods Pharmaceuticals.

RegulatoryJuly 23, 2026

FDA Accepts Supplement for Rosuvastatin Calcium by Sun Pharma

The FDA has accepted a supplemental application for Rosuvastatin Calcium submitted by Sun Pharma.

StrategyJuly 23, 2026

FDA Accepts ANDA for Rosuvastatin Calcium by Sciegen Pharmaceuticals

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Rosuvastatin Calcium submitted by Sciegen Pharmaceuticals.

RegulatoryJuly 8, 2026

FDA Approves Supplemental Application for CRESTOR (Rosuvastatin Calcium)

The FDA has approved a supplemental application for CRESTOR, a statin medication.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.